Home
Clinical Trials
PRO-POWER: Hypertension With ...

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Last Updated: 2014-04-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3184 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

NCT02238275

Hypertension

COMPLETED

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

NCT02242357

Hypertension

COMPLETED

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

NCT02242383

Hypertension

COMPLETED

An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice

NCT00982735

Hypertension

COMPLETED

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

NCT02242864

Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Essential hypertensive men and women

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female
* Aged 20 to 80 years old.
* adult with essential hypertension - either newly diagnosed and untreated, or previously treated and uncontrolled
* Sitting blood pressure: systolic BP \> 140 mmHg but \< 180 mmHg, and/or diastolic BP \> 90 mmHg but \< 110 mmHg)
* At least one cardiovascular known risk factor other than hypertension: diabetes/hyperglycaemia, cholesterol /dyslipidemia, a previous cardiovascular event, target organ damage, family history of hypertension or cardiovascular diseases, old age defined as \> 55 years (Males), \> 65 years (Females), smoking, overweight or obese patients or a combination of above risk factors
* Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication

Exclusion Criteria

* Patients with contraindications to Telmisartan use (as per the Micardis® Tablets package insert).
* Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® .
* Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
* Patients participating in any other clinical trial.
* Patients already on Micardis® alone or combination
* Pregnant females, or females breast feeding.

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 28

Al Fayyum, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 18

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 19

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 20

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 21

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 16

Alexandria West, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 17

Alexandria West, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 29

Asyut, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 10

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 11

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 12

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 1

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 2

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 3

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 4

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 5

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 6

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 7

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 8

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 9

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 22

Domiat, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 23

El Garbia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 25

Fakous - El Sharkia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 13

Kalioubya, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 27

Mansoura - El Dakahlia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 30

Menofia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 14

Minya, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 15

Minya, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 24

Poert Said, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 26

Zagazig - El Sharkia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 100

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 101

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 92

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 93

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 94

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 95

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 96

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 97

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 98

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 99

Eastern Region, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 31

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 32

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 33

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 34

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 35

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 36

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 37

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 38

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 39

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 40

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 41

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 42

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 43

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 44

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 45

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 46

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 47

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 48

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 49

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 50

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 51

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 52

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 53

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 54

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 55

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 56

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 57

Riyadh, , Saudi Arabia

Site Status